RxDoctor Payments DataLook up a doctor →

Kathy Miller, MD

Hematology & Oncology · Indianapolis, INNPI 1649236043

Payments from drug & device makers

$1,895,084in general payments, 2019–2025

Across 178 payments — averaging $10,647 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$521K
  • Amgen$316K
  • Taiho Oncology, Inc.$225K
  • AbbVie$211K
  • Merck$197K
  • Otsuka Pharmaceutical Co., Ltd.$125K
  • plus $299K from 17 others
$3,595in research payments, 2019–2025

Across 1 payment — averaging $3594.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$4K

What the payments were for

  • Consulting fees$52,57595%
  • Speaking & faculty fees$2,5005%
  • Food & beverage$4341%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,895,084 in reported general payments places this provider in the 90th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$29,172
Medicare patients
217
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib73$1,108,557
KisqaliRibociclib Succinate40$627,547
VerzenioAbemaciclib17$254,809
EliquisApixaban23$11,390
Exemestane45$10,103
Anastrozole412$6,271
Tamoxifen Citrate79$1,927
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$1,805
Oxycodone Hcl44$1,637
Morphine Sulfate ErMorphine Sulfate23$1,072
Dexamethasone17$752
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen29$698
Letrozole29$655
Prochlorperazine Maleate21$408
Tramadol Hcl30$319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$520,995$1,119,94696 claims
NovartisKisqali$26,291$627,54740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 224 hematology & oncology providers in Indiana.

Other hematology & oncology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →